SCHEMBL4397546

SCHEMBL4397546

Cc1nc(-c2ccnc(Nc3ccc(Cl)nc3)n2)sc1C

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 14/20 0.50
SYK P43405 8/20 0.50
SRC P12931 7/20 0.50
ZAP70 P43403 7/20 0.50
CDK4 P11802 10/20 0.47
CDK1 P06493 4/20 0.47
CDK7 P50613 4/20 0.47
CDK9 P50750 4/20 0.47
AURKA O14965 3/20 0.47
AURKB Q96GD4 2/20 0.47
PLK1 P53350 3/20 0.44
CCNA2 P20248 1/20 0.44
CCNE1 P24864 2/20 0.43
CCNT1 O60563 1/20 0.43
CCNB1 P14635 1/20 0.43
CCND1 P24385 1/20 0.43
CCNH P51946 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4384008 0.88 SYK (0.48) CDK2SYKSRCZAP70CDK4
SCHEMBL4385552 0.84 SYK (0.50) CDK2SYKSRCZAP70CDK4
SCHEMBL4389837 0.83 SYK (0.48) CDK2SYKSRCZAP70CDK4
SCHEMBL5220809 0.82 SYK (0.50) CDK2SYKSRCZAP70CDK4
SCHEMBL13589139 0.82 CDK2 (0.49) CDK2SYKSRCZAP70CDK4
SCHEMBL4383709 0.81 CDK2 (0.65) CDK2SYKSRCZAP70CDK4
SCHEMBL14378999 0.81 CDK2 (0.64) CDK2SYKSRCZAP70CDK4
SCHEMBL5620875 0.81 CDK2 (0.76) CDK2CDK4CDK1CDK7CDK9
SCHEMBL5621800 0.80 CDK2 (0.70) CDK2CDK4CDK1CDK7CDK9
SCHEMBL14216016 0.80 ZAP70 (0.72) CDK2SYKSRCZAP70CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP claimed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
EP-1751146-A2 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY Cyclacel Limited (GB) 2007-02-14 EP disclosed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO disclosed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318954-A1 Compounds CBR3, NR3C2, NR5A1 CDK2 1186/4885SYK 3919/4885SRC 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.